Please wait while we load the requested 10-K report or click the link below:
|For Immediate Release||The Inventor of MR Scanning™|
|Contact: Daniel Culver||An ISO 9001 Company|
|Director of Communications||Melville, New York 11747|
|E-mail: firstname.lastname@example.org||Phone: (631) 694-2929|
|www.fonar.com||Fax: (631) 390-1772|
FONAR Announces Fiscal 2017 Year-End Earnings
|*||23% Increase of Fiscal 2017 Diluted Net Income per Common Share available to Common Shareholders to $2.92, versus prior year|
|*||26% Increase of Fiscal 2017 Net Income to $23.7 million, versus prior year|
|*||33% Increase of Fiscal 2017 Income from Operations to $19.1 million, versus prior year|
|*||6% Increase of Fiscal 2017 Net Revenues to $78.0 million, versus prior year|
|*||Diluted Net Income per Common Share available to Common Shareholders for the Fiscal year ending June 30, 2017 was $2.92, including a $5.0 million impact of recorded income tax benefits|
MELVILLE, NEW YORK, September 14, 2017 – FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning™, reported today its fiscal 2017 results as of June 30, 2017. Known throughout the world for its contributions to the MRI industry, FONAR’s primary source of income is derived from its subsidiary’s (Health Management Company of American) management of 26 diagnostic imaging centers, 24 of which feature the FONAR UPRIGHT® Multi-Position™ MRI, aka Stand-Up® MRI
Basic net income per common share available to common shareholders increased 23% to $2.98 for the fiscal year ended June 30, 2017 as compared to $2.43 for the fiscal year ended June 30, 2016.
Diluted net income per common share available to common shareholders increased 23% to $2.92 for the fiscal year ended June 30, 2017 as compared to $2.38 for the fiscal year ended June 30, 2016.
Net income increased 26% to $23.7 million for the fiscal year ended June 30, 2017, as compared to $18.8 million for the fiscal year ended June 30, 2016.
Income from operations increased 33% to $19.1 million for the fiscal year ended June 30, 2017, as compared to $14.4 million for the fiscal year ended June 30, 2016.
Net revenues increased 6% to $78.0 million for the fiscal year ended June 30, 2017, as compared to $73.4 million for the fiscal year ended June 30, 2016.
Total Costs and Expenses for the fiscal year ending June 30, 2017, remained basically flat at $58.9 million as compared to $59.0 million for the fiscal year ended June 30, 2016.
For the year ended June 30, 2017, the revenues from the management of the diagnostic imaging center segment, consisting of patient and management and other fee revenue, and less the provision for bad debt for patient revenue, increased 7% to $66.8 million as compared to $62.6 million one year earlier.
At June 30, 2017, total assets increased 16% to $98.8 million, as compared to $84.9 million for the fiscal year ended June 30, 2016.
At June 30, 2017, total cash and cash equivalents increased 19% to $10.1 million, as compared to $8.5 million for the fiscal year ended June 30, 2016.
At June 30, 2017, total liabilities decreased 34% to $15.9 million, as compared to $24.1 million for the fiscal year ended June 30, 2016.
At June 30, 2017, total current liabilities decreased 31% to $14.2 million, as compared to $20.6 million for the fiscal year ended June 30, 2016.
On July 3, 2017, FONAR acknowledged the 40th anniversary of the world’s first whole-body MRI scan, thereby birthing the MRI industry. This remarkable achievement was accomplished by FONAR founder Raymond Damadian, M.D., with the assistance of graduate-students Larry Minkoff and Michael Goldsmith.
Effective June 26, 2017, FONAR stock joined the Russell 3000® Index, which has increased the Company’s membership in related index funds and ETFs (Exchange Traded Funds) to over 60, thereby giving mutual funds, institutions, and the investing community greater visibility of FONAR and helping to build shareholder value.
On March 20, 2017, Dr. Damadian was the keynote speaker at 22nd Annual Medical Technologies: A Frost & Sullivan Executive MindXchange in San Diego, CA, where he received special recognition as “the legendary inventor of the first MRI (Magnetic Resonance Imaging) machine and the innovative mind responsible for saving thousands of lives.”
On July 12, 2016 the Company’s subsidiary, Health Management Company of America (HMCA), reported three acquisitions. HMCA had purchased: 100% of the equity in Turnkey Services of New York, LLC; 100% of the equity in TK2 Equipment Management, LLC; and the remaining 50% of Diagnostic Management Services, LLC, Yonkers, NY, making it a wholly-owned subsidiary of HMCA.
On June 20, 2017, HMCA reported they had purchased a 100% interest in the FONAR MRI equipment lease related to Stand-Up MRI of Great Neck, an event that will add to FONAR’s net income and cash flow.
President and CEO Timothy R. Damadian said, “We’re pleased with our six percent (6%) growth rate in net revenue. The Company made several acquisitions in Fiscal 2017 that have added to our profitability, and we remain committed to controlling costs, which is vital in the healthcare industry where insurer reimbursement rates continue to fall year after year.
“Thankfully, the appeal of the UPRIGHT® MRI (also known as the Stand-Up® MRI) among both patients and physicians, together with my experienced and competent management team, has enabled us to thrive in a very challenging business environment.
“We will continue to seek additional opportunities consistent with our growth strategy and are committed to maintaining the Company’s very positive earnings trajectory into fiscal 2018.”
Chairman of the Board Raymond V. Damadian, M.D., added, “In Fiscal 2017, we posted a profit of $2.92 per share (Diluted Net Income per Common Share available to Common Shareholders). Our net profit margin [(Net Income / Total Revenues)] was 10 in Fiscal 2011, 26 in Fiscal 2016, and 30 for Fiscal 2017. As far as our business plan is concerned, I think that says it all.
“Regarding the Company’s ongoing research, we continue to explore the impact of our new works-in-progress technology for visualizing and quantifying the flow of cerebrospinal fluid (CSF) circulating throughout the brain and vertebral column with the patient scanned in the Upright position.
“Based on a discovery FONAR had announced on November 2, 2011, the Company was recently issued a patent for the use of the FONAR UPRIGHT® Multi-Position™ MRI to diagnose patients with Multiple Sclerosis. We are hopeful that this research will help to lead to a new understanding of the role of CSF on diseases of the brain.”
Dr. Damadian concluded, “It has been 46 years since we made the discovery that birthed the MRI industry.* We’ve had the privilege and joy of witnessing its marvelous growth from infancy. Today there are approximately 60 million MRI scans performed each year worldwide in what has become a multi-billion-dollar industry. After all these years, FONAR is finally reaping the rewards, and we’re certainly very thankful for it.”
*In 1971, Dr. Damadian’s paper in Science contained the two key discoveries that remain fundamental to the operation of every MRI scanner ever made: 1) his discovery that the relaxation times of cancerous tissues are markedly prolonged relative to those of healthy tissues and 2) his discovery there are also marked differences in relaxation times across the full spectrum of healthy tissue types.
FONAR, The Inventor of MR Scanning™, located in Melville, NY, was incorporated in 1978 and is the first, oldest and most experienced MRI company in the industry. FONAR introduced the world's first commercial MRI in 1980, and went public in 1981. FONAR's signature product is the FONAR UPRIGHT® Multi-Position™ MRI (also known as the STAND-UP® MRI), the only whole-body MRI that performs Position™ imaging (pMRI™) and scans patients in numerous weight-bearing positions, i.e. standing, sitting, in flexion and extension, as well as in the conventional lie-down position. The FONAR UPRIGHT® MRI often detects patient problems that other MRI scanners cannot because they are lie-down and "weightless-only" scanners. The patient-friendly UPRIGHT® MRI has a near-zero claustrophobic rejection rate by patients. Regarding patient comfort, as one FONAR customer stated, "If the patient is claustrophobic in this scanner, they'll be claustrophobic in my parking lot." Approximately 85% of patients are scanned sitting while watching TV.
FONAR has new works-in-progress technology for visualizing and quantifying the flow of cerebrospinal fluid (CSF) which circulates throughout the brain and vertebral column at the rate of 32 quarts per day. This imaging and quantifying of the dynamics of this vital life-sustaining physiology of the body’s neurologic system has been made possible first by FONAR’s introduction of the MRI and now by this latest works-in-progress method for quantifying CSF flow in all the normal positions of the body, particularly in its upright flow against gravity. Patients with whiplash or other neck injuries as well as patients with childhood autism, Multiple Sclerosis, Alzheimer's disease, Amyotrophic Lateral Scherosis (Lou Gehrig's disease), Parkinson's disease and dementia are among those who FONAR believes are likely to benefit from this new understanding of CSF flow physiology.
FONAR’s substantial list of patents includes recent patents for its technology enabling full weight-bearing MRI imaging of all the gravity sensitive regions of the human anatomy, especially the brain, extremities and spine. FONAR’s UPRIGHT® Multi-Position™ MRI is the only scanner licensed under these patents.
UPRIGHT® and STAND-UP® are registered trademarks and The Inventor of MR Scanning™, Full Range of Motion™, Multi-Position™, Upright Radiology™, The Proof is in the Picture™, True Flow™, pMRI™, Spondylography™, Dynamic™, Spondylometry™, CSP™, and Landscape™, are trademarks of FONAR Corporation.
This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company's financial results may be found in the company's filings with the Securities and Exchange Commission.
CONSOLIDATED BALANCE SHEETS
|Cash and cash equivalents||$||10,139,621||$||8,528,309|
|Accounts receivable – net of allowances for doubtful accounts of $190,244 and $284,279 at June 30, 2017 and 2016, respectively||4,321,760||4,370,155|
|Medical receivables –net of allowances for doubtful accounts of $19,853,318 and $17,451,782 at June 30, 2017 and 2016, respectively||11,744,704||10,126,397|
|Management and other fees receivable – net of allowances for doubtful accounts of $12,859,750 and $13,553,005 at June 30, 2017 and 2016, respectively||18,593,894||15,637,831|
|Management and other fees receivable – related party medical practices – net of allowances for doubtful accounts of $582,001 and $392,505 at June 30, 2017 and 2016, respectively||4,959,598||4,063,539|
|Costs and estimated earnings in excess of billings on uncompleted contracts||736,061||—|
|Prepaid expenses and other current assets||1,293,806||759,042|
|Total Current Assets||53,413,706||45,559,573|
|Deferred income tax asset||17,861,777||13,042,360|
|Property and Equipment – Net||16,462,504||14,512,706|
|Other Intangible Assets – Net||6,644,504||7,719,358|
CONSOLIDATED BALANCE SHEETS
|Current portion of long-term debt and capital leases||$||180,090||$||2,447,693|
|Other current liabilities||7,203,278||10,826,793|
|Unearned revenue on service contracts||4,641,534||4,678,914|
|Billings in excess of costs and estimated earnings on uncompleted contracts||—||206,623|
|Total Current Liabilities||14,236,003||20,613,247|
|Deferred income tax liability||331,527||481,779|
|Due to related party medical practices||227,543||245,041|
|Long-term debt and capital leases, less current portion||336,761||2,059,236|
|Total Long-Term Liabilities||1,616,610||3,498,052|
CONSOLIDATED BALANCE SHEETS
|Class A non-voting preferred stock $.0001 par value; 453,000 shares authorized at June 30, 2017 and 2016, 313,438 issued and outstanding at June 30, 2017 and 2016||$||31||$||31|
|Preferred stock $.001 par value; 567,000 shares authorized at June 30, 2017 and 2016, issued and outstanding – none||—||—|
|Common stock $.0001 par value; 8,500,000 shares authorized at June 30, 2017 and 2016, 6,299,154 and 6,062,809 issued at June 30, 2017 and 2016, respectively; 6,287,511 and 6,051,166 outstanding at June 30, 2017 and 2016, respectively||630||607|
|Class B convertible common stock (10 votes per share) $.0001 par value; 227,000 shares authorized at June 30, 2017 and 2016, 146 issued and outstanding at June 30, 2017 and 2016||—||—|
|Class C common stock (25 votes per share) $.0001 par value; 567,000 shares authorized at June 30, 2017 and 2016, 382,513 issued and outstanding at June 30, 2017 and 2016||38||38|
|Paid-in capital in excess of par value||179,131,780||173,702,335|
|Notes receivable from employee stockholders||(16,546||)||(23,879||)|
|Treasury stock, at cost – 11,643 shares of common stock at June 30, 2017 and 2016||(675,390||)||(675,390||)|
|Total Fonar Corporation’s Stockholders’ Equity||77,437,154||52,379,732|
|Total Stockholders' Equity||82,909,953||60,776,307|
|Total Liabilities and Stockholders' Equity||$||98,762,566||$||84,887,606|
CONSOLIDATED STATEMENTS OF INCOME
|For the Years Ended June 30,|
|Product sales – net||$||1,572,148||$||1,276,882||$||1,820,979|
|Service and repair fees – net||9,537,040||9,396,736||9,549,316|
|Service and repair fees – related parties – net||110,000||110,000||110,000|
|Patient fee revenue, net of contractual allowances and discounts||36,400,600||32,985,809||28,153,598|
|Provision for bad debts for patient fee||(16,171,434||)||(14,539,786||)||(12,770,249||)|
|Management and other fees – net||38,361,514||36,633,230||34,805,627|
|Management and other fees – related party medical practices – net||8,226,718||7,505,339||7,381,725|
|Total Revenues – Net||78,036,586||73,368,210||69,050,996|
|Costs and Expenses|
|Costs related to product sales||931,501||1,254,328||1,882,230|
|Costs related to service and repair fees||2,996,736||2,148,143||2,189,373|
|Costs related to service and repair fees – related parties||34,564||25,147||25,220|
|Costs related to patient fee revenue||8,987,673||9,418,935||7,939,524|
|Costs related to management and other fees||20,828,581||21,949,583||20,970,116|
|Costs related to management and other fees – related party medical practices||4,273,370||4,074,762||3,883,953|
|Research and development||1,480,670||1,631,846||1,812,398|
|Selling, general and administrative, inclusive of compensatory element of stock issuances of $2,397,276, $2,006 and $53,200 for the years ended June 30, 2017, 2016 and 2015, respectively||19,407,411||18,509,850||17,448,305|
|Total Costs and Expenses||58,940,506||59,012,594||56,151,119|
|Income from Operations||19,096,080||14,355,616||12,899,877|
|Other Income and (Expenses):|
|Other (expense) income – net||(1,156||)||190,560||394,810|
|Income before benefit for income taxes and noncontrolling interests||19,316,364||14,508,246||12,817,862|
|Benefit for Income Taxes||4,362,434||4,287,271||2,612,521|
|Net Income – Noncontrolling Interests||(4,058,177||)||(3,070,892||)||(2,519,732||)|
|Net Income – Attributable to FONAR||$||19,620,621||$||15,724,625||$||12,910,651|
CONSOLIDATED STATEMENTS OF INCOME (Continued)
|For the Years Ended June 30,|
|Net Income Available to Common Stockholders||$||18,390,586||$||14,702,834||$||12,071,670|
|Net Income Available to Class A Non-Voting Preferred Stockholders||$||916,769||$||761,561||$||625,309|
|Net Income Available to Class C Common Stockholders||$||313,266||$||260,230||$||213,672|
|Basic Net Income Per Common Share Available to Common Stockholders||$||2.98||$||2.43||$||2.00|
|Diluted Net Income Per Common Share Available to Common Stockholders||$||2.92||$||2.38||$||1.95|
|Basic and Diluted Income Per Share – Class C Common||$||0.82||$||0.68||$||0.56|
|Weighted Average Basic Shares Outstanding – Common Stockholders||6,161,599||6,050,893||6,050,632|
|Weighted Average Diluted Shares Outstanding – Common Stockholders||6,289,103||6,178,397||6,178,136|
|Weighted Average Basic and Diluted Shares Outstanding – Class C Common||382,513||382,513||382,513|
The following information was filed by Fonar Corp (FONR) on Friday, September 15, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Fonar Corp's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Fonar Corp.